海角社区

Andrew J. Gerber, MD, PhD, is medical director and CEO of the Austen Riggs Center and an associate clinical professor in the Division of Child and Adolescent Psychiatry at Columbia University Medical Center. He is an associate clinical professor at the Child Study Center, Yale University. He is an adjunct associate professor of Psychological & Brain Sciences in the College of Natural Sciences at University of Massachusetts Amherst. He is the former co-director of the Sackler Parent-Infant Program at Columbia University, former director of the MRI Research Program at the New York State Psychiatric Institute, and former director of research at the Columbia University Center for Psychoanalytic Training and Research. While in New York, he also had a private psychoanalytic practice.

Dr. Gerber completed a PhD in psychology at the Anna Freud Centre and University College London where he studied with Peter Fonagy and Joseph Sandler, investigating the process and outcome of psychoanalysis and psychoanalytic psychotherapy in young adults. He completed his medical and psychiatric training at Harvard Medical School, Cambridge Hospital, and Weill Cornell and Columbia medical schools and his psychoanalytic training at Columbia. He trained as a research fellow with Bradley Peterson at the New York State Psychiatric Institute in brain imaging and child psychiatry. He has published and received grants in the areas of developmental psychopathology, attachment, and functional neuroimaging of dynamic processes, including social cognition and transference. He has also been involved in planning and teaching psychoanalytic research as head of the Science Department at the American Psychoanalytic Association and chair of the Committee on Scientific Activities, secretary of the Psychoanalytic Psychodynamic Research Society, and a member of the psychotherapy research committees of the American Academy of Child and Adolescent Psychiatry.

Dr. Gerber is married to Andrea Gerber, PhD, who is a clinical psychologist. They have two young daughters, Samantha and Lila.

Dr. Gerber鈥檚 published scholarship shows his deep passion for research. For a list (and downloadable copies) of Dr. Gerber's publications, see: http://www.researchgate.net/profile/Andrew_Gerber

Jane G. Tillman, PhD, ABPP, is the Evelyn Stefansson Nef Director of the Erikson Institute for Education and Research at the Austen Riggs Center, a long-term psychiatric hospital and treatment center in Stockbridge, Massachusetts. A board-certified clinical psychologist and a psychoanalyst, Dr. Tillman is an assistant clinical professor at the Yale Child Study Center and a clinical instructor in psychology in the Department of Psychiatry at the Harvard Medical School. Dr. Tillman serves on the editorial boards of Psychoanalytic Psychology, and the Journal of the American Psychoanalytic Association. She is the past-president of the Section on Women, Gender, and Psychoanalysis of Division 39, served two terms as the chair of the Ethics Committee for Division 39, and is a past board member of the Western Massachusetts Albany Association for Psychoanalytic Psychology (WMAAPP). 

RESEARCH AND SCHOLARSHIP
Dr. Tillman is the principal investigator on several externally funded studies related to understanding the contributors to suicidal states of mind and suicidal behavior.  She directs the Suicide Research and Education Initiative for the Erikson Institute. Dr. Tillman has presented and published on a wide variety of topics including dissociation, psychosis, religion, impasses in treatment, embodiment, clinical and professional ethics, research methodology, identifying markers for acute risk of suicide, and the effect of patient suicide on clinicians. She has also written on the intergenerational transmission of suicide.  

TRAINING
Dr. Tillman earned her AB from the University of North Carolina-Chapel Hill, and MDiv from Duke University, a PhD in clinical psychology from the University of Tennessee-Knoxville, and completed a pre-doctoral internship at the Dartmouth Medical School. She completed a four-year Fellowship in psychoanalytic psychotherapy at the Austen Riggs Center and is a graduate of the Berkshire Psychoanalytic Institute.

For a list (and downloadable copies) of Dr. Tillman's publications, see: http://www.researchgate.net/profile/Jane_Tillman

Neil B. Friedman, M.D., FACS, is Director of The Hoffberger Breast Center at Mercy as well as Medical Director of The Weinberg Center for Women's Health and Medicine at Mercy. As a catalyst for advancing breast cancer treatment, Dr. Friedman has partnered with many prestigious national and local organizations to improve the treatment options for women with breast cancer. Likewise, on a very personal level, he partners with each of his patients and their families to help them face the challenges and triumphs of living with a breast cancer diagnosis. Dr. Friedman led the charge to bring IORT, Intraoperative Radiotherapy, to Mercy making it the first hospital in Maryland to offer this leading-edge technology. Dr. Friedmane began his medical career as Chief Resident at the nationally renowned Memorial Sloan-Kettering Cancer Center in New York. He is a Board Certified breast cancer doctor who is dedicated to the search for a cure for cancer. His team continues to lead breast cancer initiatives and introduce best-in-practice breast care treatment options, including Intraoperative Radiotherapy (IORT), an innovative, single-dose radiation treatment, to patients. Dr. Friedman was named Humanitarian of the Year by the Mildred Mindell Cancer Foundation for his efforts in the fight against breast cancer. He has served as a national spokesperson for breast cancer prevention for major organizations such as Bath & Bodyworks. Dr. Friedman has been the Chairman of the American Cancer Society’s Research Administrative Committee, a member of its Executive and Professional Education Committees, and served on its Board of Directors. He has also been involved with the Susan G. Komen Breast Cancer Foundation. Dr. Friedman leads a team of clinicians devoted to breast cancer education, advocating the latest advancements in diagnosis and treatment of breast cancer at a number of conferences, continuing education forums, and patient seminars. Dr. Neil Friedman remains committed in his career to find optimal treatments for breast cancer. Some of his accomplishments include: • Named a “Top Doc” by Baltimore magazine in the Breast Surgery category • Named Humanitarian of the Year by the Mildred Mindell Cancer Foundation • The Breast Center at Mercy Medical Center first in Maryland to offer IORT Treatment • Research on cancer has been published in American Journal of Public Health(APHA) and the Journal of Immunotherapy

As Managing Director 鈥� Data Science for Youth Villages, Sarah Hurley, Ph.D., is responsible for the management of research activities across the organization. She supervises the outcome evaluation process that tracks thousands children and youth after they leave Youth Villages鈥� programs. She also manages funded research projects, develops research-based policy recommendations, and presents research results nationwide.

Dr. Hurley began her career in the biostatistics division at Baptist Memorial Hospital in Memphis, held several positions at the Ohio Department of Health, and served as interim executive director of an AIDS service organization. She also taught at the undergraduate level for 12 years at the University of Michigan-Flint, Pittsburg State University and Arkansas State University. She earned her doctorate degree in health outcomes and policy research from the University of Tennessee Health Science Center in 2008.

Jacquelyn Campbell is a national leader in research and advocacy in the field of domestic violence or intimate partner violence (IPV). Her expertise is frequently sought by national and international policy makers in exploring IPV and its health effects on families and communities. 

Her most recent research in health sequelae has been foundational for the areas of the intersection of HIV and violence against women and how head injuries and strangulation from intimate partner violence can result in undiagnosed and untreated Traumatic Brain Injury. She has consistently advocated for addressing health inequities of marginalized women in this country and globally affected by experiences of violence.  

She has served as Principle Investigator on 14 federally funded collaborative research investigations through the National Institutes of Health, National Institutes of Justice, Department of Defense, the Department of Justice (Office of Violence Against Women), and Centers for Disease Control to examine intimate partner homicide and other forms of violence against women as well as interventions and policy initiatives to improve the justice and health care system response. This work has paved the way for a growing body of interdisciplinary knowledge about experiences of violence and health outcomes, risk assessment for lethal and near-lethal domestic violence, and coordinated system (justice, social services, and health) responses to address intimate partner violence.

Dr. Campbell has published more than 270 articles, 56 book chapters and seven books, in addition to developing the Danger Assessment, an instrument to assist abused women in accurately determining their level of danger. The Danger Assessment is also the basis of the Lethality Assessment Program (MNADV LAP) for first responders to assess risk of homicide of domestic violence survivors and connect those at high risk with domestic violence services. In collaboration with Dr. Nancy Glass, originator of myPlan, a decision aid for IPV survivors, she is leading an NIH-funded cultural adaptation of myPlan for immigrant and indigenous women.

Elected to the Institute of Medicine in 2000, Dr. Campbell also was the Institute of Medicine/American Academy of Nursing/American Nurses' Foundation Senior Scholar in Residence and was founding co-chair of the IOM Forum on the Prevention of Global Violence. Other honors include the Pathfinder Distinguished Researcher by the Friends of the National Institute of Health National Institute for Nursing Research, Outstanding Alumna and Distinguished Contributions to Nursing Science Awards, Duke University School of Nursing, the American Society of Criminology Vollmer Award, and being named one of the inaugural 17 Gilman Scholars at Johns Hopkins University. She is on the Board of Directors for Futures Without Violence, is an active member of the Johns Hopkins Women鈥檚 Health Research Group, and has served on the boards of the House of Ruth Battered Women's Shelter and four other shelters. She was a member of the congressionally appointed U.S. Department of Defense Task Force on Domestic Violence. 

Dr. Walter has spent his 28-year academic career at a primarily undergraduate campus that has just recently been designated an 鈥淓merging Research Institution.鈥� He has served in the Department of Biology (9 years) and then moved to the Department of Chemistry & Biochemistry to assist in development of a Biochemistry undergraduate program. Dr. Walter developed partnership grant proposals aimed towards providing scholarships for student groups that are underrepresented in the sciences (URM). In Fall 2013, he was awarded a Bridges to Biomedicine (B2B) grant wherein Texas State University is partnering with two Alamo Community College campuses to establish a program focused on increasing success of URM students in the biomedical sciences upon transfer to the baccalaureate institution. The B2B program addresses the most important obstacles to upper-division degree completion experienced by students showing an early commitment to a biomedical career. Additionally, Dr. Walter serves as Co-PI for the South Texas Doctoral Bridge Program (STDBP).  The STDBP is aimed at student matriculation from the MS degree into highly competitive doctoral programs. The STDBP is established between the Univ. of Texas Health Science Center at San Antonio (UTHSCSA, medical school) and Texas State University. The STDBP is designed to provide a combination of mentoring and student development activities as well as enhance didactics and research training during a thesis-based M.S. degree in Biochemistry.

Michelle Litchman, PhD, FNP-BC, FAANP, is an expert in diabetes care and using social media and other online resources to monitor how people with diabetes manage their own health in the real world. 

Litchman is an Assistant Professor at the College of Nursing and School of Medicine. Her position includes research, teaching, and clinical work at the Utah Diabetes and Endocrinology Center. She is passionate about teaching and precepts health sciences students and teaches didactic courses at the College of Nursing. Dr. Litchman鈥檚 program of research emphasizes the social context of chronic disease management across the lifespan with a particular emphasis on diabetes and technology. Her research examines online environments to understand the influence of peer support on health outcomes and diabetes management in the 鈥渞eal-world鈥�. Dr. Litchman also examines family dynamics to understand how diabetes management is supported or derailed, and how technology might be helpful.

Supporting confident decision-making by identifying nutrition or food safety information gaps and filling them. Knowledge of multisectoral decision-making, conflict of interest issues, research investments, scientific integrity and food safety. Dr. Jones has a strong scientific background in the food, agriculture and chemical industries, and brings over 20 years of global experience in industry and government. She leads IAFNS鈥檚 multi-sector scientists, trustees and staff to extend the organization鈥檚 contribution to and impact within diverse scientific and health communities. Leveraging the input of government, industry and academic scientists she catalyzes the advancement of science. In doing so, she is expert in multi-sectoral processes and research investments that benefit public health.

Paul Pfleiderer received BA, MPhil, and PhD degrees from Yale University, all in the field of economics. He has been teaching at Stanford since 1981. His research, much of which has been jointly pursued with Anat Admati, another professor of finance at the GSB, is generally concerned with issues that arise when agents acting in financial markets are differentially informed. His current research concerns corporate governance. In addition to his academic research, Professor Pfleiderer has consulted for various corporations and banks and has been involved in developing risk models and optimization software for use by portfolio managers.

Sumit Chanda earned his Ph.D. from Stanford University in 2001, and received his post-doctoral training at the Genomics Institute of the Novartis Research Foundation (GNF). He subsequently transitioned to a Group Leader position, and established his research group in the Division of Cellular Genomics at GNF. In 2007, he joined the Infectious and Inflammatory Disease Center at Sanford-Burnham Medical Research Institute as an Associate Professor. Dr. Chanda also holds an Adjunct Professor appointment at the Salk Institute for Biological Studies, as well as a Visiting Scientist position at the Genomics Institute of the Novartis Research Foundation.

Anshuman 鈥淎R鈥� Razdan, vice president for research and innovation at the University of Oregon, was elected to the 2022 class of fellows of the National Academy of Inventors in recognition of his contributions to the field of computer science. Razdan holds four patents, including on 3-D face authentication and document exploitation as well as image processing. Razdan came to the UO in 2022 after serving as the associate vice president of research development at the University of Delaware. 

 researches and teaches ways to facilitate greater alignment between one’s intentions and behaviors to promote well-being. 
More information: 
Dariotis investigates biosocial determinants of risk-taking, decision-making, stress responsivity and coping, and prevention and intervention programs (e.g., mindfulness-related). She addresses “wicked” problems through whole person research integrating theoretical and methodological approaches across many disciplines—public health, prevention science, biostatistics, evaluation and implementation sciences, behavioral endocrinology, and developmental psychopathology.
Affiliation:
Dariotis is a professor for the Department of  in the  at the . She is also affiliate faculty in , , , , 

William C. Harris, Ph.D., served as Science Foundation Ireland’s founding director general and was responsible for leading it in its early years and for developing the eventual legislation to formally establish an independent SFI. He subsequently was founding president and CEO of Science Foundation Arizona.
Prior to his work at SFI, Bill served as vice president of Research for the University of South Carolina. He served in significant leadership roles at the US National Science Foundation, including developing NSF’s 25 initial Science and Technology centers and leading the Mathematical and Physical Sciences directorate. He served as deputy director of Columbia University’s Earth Institute and led development of Biosphere 2 as a western campus of Columbia.
Bill is the co-author, with Stephen Beschloss, of Adrift: Charting Our Course Back to a Great Nation (Prometheus, 2011). A former chemistry professor at Furman University, he earned his BS degree from William and Mary and his PhD from USC. Bill holds honorary doctorates from the University of Ireland and Northern Arizona University. He is co-founder and director of Innovation Advisory Partners.

Daniel King, MD, PhD, is a former Howard Hughes research scholar at the National Institutes of Health and trained in genomics and bioinformatics at the Wellcome Trust Sanger Institute, where he developed software tools to perform mosaic copy number detection. During his time at the Wellcome Trust Sanger Institute, he spearheaded copy number analysis for 36,000 exome samples in the Deciphering Developmental Disorder Rare Disease project. The results from this work characterized unprecedented detail in the landscape and architecture of developmental disorders, was published in Nature and Lancet, and led to several first author publications.
Following medical and graduate school, Dr. King pursued a medical oncology fellowship under the ABIM Research Track pathway at Stanford University. A core focus of his fellowship research involved circulating tumor DNA (ctDNA), which included the computational design of a ctDNA detection panel for pancreas cancer and laboratory validation. This work extended to fragmentomics—a computational analysis of circulating DNA fragment ends as a biomarker of cancer for early detection. From here, Dr. King created a large biobank of pancreas cancer specimens consisting of nearly 500 clinical blood samples from approximately 250 patients. He went on to link this biobank with a large clinical research database built in pancreatic cancer to mine and associate clinical data with translational correlates.

Jonathan W. Friedberg, M.D., is Director of the James P. Wilmot Cancer Institute and the Samuel Durand Professor of Medicine at the University of Rochester Medical Center. He is a driving force behind the operations of Wilmot’s clinical and research programs, leading a team of associate directors who help make decisions surrounding Wilmot’s clinical, research, education, and community outreach missions.
Dr. Friedberg serves as the editor-in-chief of the Journal of Clinical Oncology (JCO), the flagship journal of the American Society of Clinical Oncology (ASCO). He began this five-year term in June 2021. Prior to his editor-in-chief role, he served as associated editor of JCO. He has also served as a reviewer and on editorial boards for a number of medical journals.
Friedberg is a chair of the lymphoma committee in the SWOG group of the NCI National Clinical Trials Network and is an independently R01-funded investigator in the field of lymphoid malignancies.
Dr. Friedberg received his medical degree from Harvard Medical School. His postgraduate training included an internship and residency at Massachusetts General Hospital. He also completed a medical oncology and hematology fellowship at Dana-Farber/Partners Cancer Care in Boston. Dr. Friedberg also has an M.M.Sc. degree from Harvard Medical School in clinical investigation. He holds subspecialty certification in Medical Oncology and Hematology.
His research interests focus on development of novel therapies for patients with lymphoma. He formerly received a Scholar in Clinical Research award from the Leukemia & Lymphoma Society, based upon his work with an oral inhibitor of a protein called Syk, which demonstrated efficacy in the treatment of several different forms of lymphoma. He is currently funded as PI of the ILyAD trial, evaluating patients with follicular lymphoma receiving rituximab with a vitamin D intervention. As chair of SWOG, he is co-leader of the current North American intergroup effort in advanced stage Hodgkin lymphoma. He is also a founding member of the Lymphoma Epidemiology of Outcomes Consortium.

Dr. Mehmood Khan’s distinguished career has included several senior corporate roles, including Vice Chairman and Chief Scientific Officer of Global Research and Development at PepsiCo, and President of Global R&D at Takeda Pharmaceuticals.
Before moving into the private sector Dr. Khan was a faculty member in endocrinology at the Mayo Clinic and Medical School, where he served as Director of the Diabetes, Endocrine and Nutritional Trials Unit. He also led programs in diabetes, endocrinology, metabolism, and nutrition in Minneapolis.
Dr. Khan is a member of the Board of Directors of Reckitt Benckiser and of the Saudi Research, Development, and Innovation Authority (RDIA), Executive Chairman of Life Biosciences, a member of the Saudi National Biotechnology Strategy Steering Committee, and Chairman of the Visiting Committee on Advanced Technology of the United States’ National Institute of Standards and Technology (NIST).
Dr. Khan earned his medical degree from the University of Liverpool School of Medicine, England, and completed a fellowship in clinical endocrinology and nutrition in the Department of Medicine and Food Science and Nutrition at the University of Minnesota, Minneapolis. He is a Fellow of the Royal College of Physicians in London, a Fellow of the American College of Endocrinology, and an Elected Fellow in the Department of Pharmacology at University of Oxford.